Cefepime and continuous renal replacement therapy (CRRT): In vitro permeability of two CRRT membranes and pharmacokinetics in four critically ill patients

Clinical Therapeutics

Volumn 27, Issue 5, 2005, Pages 599-608

  Isla, Arantxazu ^a   Gascón, Alicia Rodríguez ^a   Maynar, Javier ^b   Arzuaga, Alazne ^a   Toral, Darío ^c   Pedraz, José Luis ^a  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^b HOSPITAL TXAGORRITXU   (Spain)

^c HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

Cefepime; Continuous renal replacement therapies; Pharmacokinetics

Indexed keywords

BOVINE SERUM ALBUMIN; CEFEPIME; DIALYSIS FLUID; POLYACRYLONITRILE; POLYSULFONE; RINGER LACTATE SOLUTION;

ADULT; AGED; ANALYTIC METHOD; ARTICLE; BLOOD SAMPLING; CASE REPORT; CONCENTRATION (PARAMETERS); CORRELATION ANALYSIS; CRITICAL ILLNESS; DIALYSATE; DRUG CLEARANCE; DRUG DIFFUSION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG PENETRATION; FILTER; HEMODIALYSIS; HEMOFILTRATION; HUMAN; IN VIVO STUDY; LIQUID; LIQUID CHROMATOGRAPHY; MALE; MEASUREMENT; MEMBRANE PERMEABILITY; PATIENT; SAMPLE; SIMULATION; STEADY STATE; TIME;

ACRYLIC RESINS; ACRYLONITRILE; ADOLESCENT; AGED; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; CEPHALOSPORINS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CRITICAL ILLNESS; HEMOFILTRATION; HUMANS; INTENSIVE CARE UNITS; MALE; MEMBRANES, ARTIFICIAL; METABOLIC CLEARANCE RATE; MIDDLE AGED; PERMEABILITY; POLYMERS; SULFONES;

EID: 20644458758     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2005.05.004     Document Type: Article

References (37)

1. Barradell LB, and Bryson HM Cefepime. A review of its antibacterial activity, pharmacokinetic profile and therapeutic use Drugs 47 1994 471 505
2. Hancock RE, and Bellido F Factors involved in the enhanced efficacy against gram-negative bacteria of fourth generation cephalosporins J Antimicrob Chemother 29 Suppl A 1992 1 6
3. Cappelletty DM Evaluation of several dosing regimens of cefepime, with various simulations of renal function, against clinical isolates of Pseudomonas aeruginosa in a pharmacodynamic infection model Antimicrob Agents Chemother 43 1999 129 133
4. Malone RS, Fish DN, Abraham E, and Teitelbaum I Pharmacokinetics of cefepime during continuous renal replacement therapy in critically ill patients Antimicrob Agents Chemother 45 2001 3148 3155
5. Lipman J, Wallis SC, and Rickard C Low plasma cefepime levels in critically ill septic patients: Pharmacokinetic modeling indicates improved troughs with revised dosing Antimicrob Agents Chemother 43 1999 2559 2561
6. Van der Auwera P, and Santefla PJ Pharmacokinetics of cefepime: A review J Antimicrob Chemother 32 1993 103 115
7. Allaouchiche B, Breilh D, and Jaumain H Pharmacokinetics of cefepime during continuous venovenous hemodiafiltration Antimicrob Agents Chemother 41 1997 2424 2427
8. Wuyts B, Bernard D, and Van den Noortgate N Reevaluation of formulas for predicting creatinine clearance in adults and children, using compensated creatinine methods Clin Chem 49 2003 1011 1014
9. Shah VP, Midha KK, and Findlay JW Bioanalytical method validation-a revisit with a decade of progress Pharm Res 17 2000 1551 1557
10. US Food and Drug Administration Guidance for Industry: Bioanalytical Methods Validation for Human Studies 1998 Center for Drug Evaluation and Research Rockville, Md
11. Golper TA, Wedel SK, and Kaplan AA Drug removal during continuous arteriovenous hemofiltration: Theory and clinical observations Int J Artif Organs 8 1985 307 312
12. Bauer LA, and Gibaldi M Computation of model-independent pharmacokinetic parameters during multiple dosing J Pharm Sci 72 1983 978 979
13. Lee CC, and Marbury TC Drug therapy in patients undergoing hemodialysis: Clinical pharmacokinetic considerations Clin Pharm 9 1984 42 66
14. Kroh UF Drug administration in critically ill patients with acute renal failure New Horiz 3 1995 748 759
15. Krueger WA, Schroeder TH, and Hutchison M Pharmacokinetics of meropenem in critically ill patients with acute renal failure treated by continuous hemodiafiltration Antimicrob Agents Chemother 42 1998 2421 2424
16. Golper TA Drug removal during continuous hemofiltration or hemodialysis Contrib Nephrol 93 1991 110 116
17. Kalman D, Barriere SL, and Johnson BL Jr. Pharmacokinetic disposition and bactericidal activities of cefepime, ceftazidime, and cefoperazone in serum and blister fluid Antimicrob Agents Chemother 36 1992 453 457
18. Relton S, Greenberg A, and Palevsky PM Dialysate and blood flow dependence of diffusive solute clearance during CVVHD ASAIO J 38 1992 M691 M696
19. Zarowitz BJ, Anandan JV, and Dumler F Continuous arteriovenous hemofiltration of aminoglycoside antibiotics in critically ill patients J Clin Pharmacol 26 1986 686 689
20. Lau AH, and Kronfol NO Elimination of flucytosine by continuous hemofiltration Am J Nephrol 15 1995 327 331
21. Emest D, and Cutler DJ Gentamicin clearance during continuous arteriovenous hemodiafiltration Crit Care Med 20 1992 586 589
22. Joy MS, Matzke GR, Frye RF, and Palevsky PM Determinants of vancomycin clearance by continuous venovenous hemofiltration and continuous venovenous hemodialysis Am J Kidney Dis 31 1998 1019 1027
23. Matzke GR, Frye RF, Joy MS, and Palevsky PM Determinants of ceftriaxone clearance by continuous venovenous hemofiltration and hemodialysis Pharmacotherapy 20 2000 635 643
24. Matzke GR, Frye RF, Joy MS, and Palevsky PM Determinants of ceftazidime clearance by continuous venovenous hemofiltration and continuous venovenous hemodialysis Antimicrob Agents Chemother 44 2000 1639 1644
25. Kieft H, Hoepelman AI, and Knupp CA Pharmacokinetics of cefepime in patients with the sepsis syndrome J Antimicrob Chemother 32 1993 1117 1122
26. Padillo FJ, Briceno J, and Cruz A Randomized clinical trial of the effect of intravenous fluid administration on hormonal and renal dysfunction in patients with obstructive jaundice undergoing endoscopic drainage Br J Surg 92 2005 39 43
27. Hanes SD, Wood GC, and Herring V Intermittent and continuous ceftazidime infusion for critically ill trauma patients Am J Surg 179 2000 436 440
28. Arzuaga A, Maynar J, and Gascon AR Influence of renal function on the pharmacokinetics of piperacillin/tazobactam in intensive care unit patients during continuous venovenous hemofiltration J Clin Pharmacol 45 2005 168 176
29. Reed RL II, Ericsson CD, and Wu A The pharmacokinetics of prophylactic antibiotics in trauma J Trauma 32 1992 21 27
30. Townsend PL, Fink MP, Stein KL, and Murphy SG Aminoglycoside pharmacokinetics: Dosage requirements and nephrotoxicity in trauma patients Crit Care Med 17 1989 154 157
31. Botha FJ, van der Bijl P, Seifart HL, and Parkin DP Fluctuation of the volume of distribution of amikacin and its effect on once-daily dosage and clearance in a seriously ill patient Intensive Care Med 22 1996 443 446
32. Fernandez de Gatta MM, Mendez ME, and Romano S Pharmacokinetics of amikacin in intensive care patients J Clin Pharm Ther 21 1996 417 421
33. Hyatt JM, McKinnon PS, Zimmer GS, and Schentag JJ The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents Clin Pharmacokinet 28 1995 143 160
34. Craig WA Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins Diagn Microbiol Infect Dis 22 1995 89 96
35. Craig WA Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men Clin Infect Dis 26 1998 1 10
36. Álvarez-Lerma F, Palomar M, and Olaechea P Estudio nacional de vigilancia de infección nosocomial en unidades de cuidados intensivos. Informe del año 2000 Medicina Intensiva 26 2002 39 50
37. NCCLS document M100-S14 National Committee for Clinical Laboratory Standards Performance Standards for Antimicrobial Susceptibility Testing; Fourteenth Informational Supplement 2004 National Committee for Clinical Laboratory Standards Wayne, Pa